Gao Lei, Wu Xingjun, Zhang Libo, Dai Yang, Zhu Zhe, Zhi Yunqing, Wang Kaijing
Department of Thoracic Surgery, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China (USTC), Hefei, Anhui, 230001, People's Republic of China.
Department of Oncology, Jiangsu Taizhou NO. 2 People Hospital, Jiangsu, People's Republic of China.
Onco Targets Ther. 2021 Mar 2;14:1605-1611. doi: 10.2147/OTT.S296031. eCollection 2021.
Colorectal cancer (CRC) is one of the most common types of malignancies, and radiochemotherapy (RCT) followed by surgery is the recommended approach for CRC treatment. However, some cases do not respond to first-line conventional chemotherapy or even progress further after treatment. Moreover, there is a risk of severe side effects, such as radiodermatitis. Therefore, identifying predictors for RCT sensitivity is an essential step toward predicting and eventually overcoming resistance.
We used integrative bioinformatics analysis and experimental validation to show that regenerating family member 4 () may be a potential biomarker for RCT sensitivity in CRC.
, whose expression is upregulated in some CRC tissues and downregulated in RCT-sensitive CRC cells, was identified as a potential genetic marker for RCT sensitivity in CRC. Immunohistochemistry-based tissue microarray of human CRC was used to experimentally validate data obtained from the bioinformatics analysis.
Collectively, these results indicate that may be a potential biomarker for RCT sensitivity in CRC.
结直肠癌（CRC）是最常见的恶性肿瘤类型之一，放疗联合化疗（RCT）后行手术是CRC治疗的推荐方法。然而，一些病例对一线传统化疗无反应，甚至在治疗后病情进一步进展。此外，还存在严重副作用的风险，如放射性皮炎。因此，确定RCT敏感性的预测指标是预测并最终克服耐药性的关键一步。
我们使用综合生物信息学分析和实验验证表明，再生家族成员4（ ）可能是CRC中RCT敏感性的潜在生物标志物。
在一些CRC组织中表达上调，而在RCT敏感的CRC细胞中表达下调，被确定为CRC中RCT敏感性的潜在遗传标志物。基于免疫组织化学的人CRC组织芯片用于实验验证从生物信息学分析中获得的数据。
总体而言，这些结果表明 可能是CRC中RCT敏感性的潜在生物标志物。
